Related to Lundbeck Pays Genmab €7.5 Up Front in Deal Focused on CNS Diseases

• Rhenovia and USC to Collect $2.3M Grant to Study Brain Functions and Disorders
  
• Janssen to Invest at least $38M in CNS Collaboration with NeuroSearch
  
• Genmab and GSK Achieve Accelerated FDA Clearance of CLL Drug
  
• Proximagen Takes Over Biovitrum’s Drug Discovery Subsidiary and Certain CNS Candidates
  
• Genzyme to Evaluate to-BBB’s Technology for Delivering Biologics to the Brain
  
• Genmab to Sell Manufacturing Facility and Cut 300 Jobs
  
• Developmental Delay May Stem from Nicotinic Receptor Deletion
  
• Evotec Awarded Roughly $3.74 by German Government to Hunt for Neuroprotective Compounds
  
• Investigators Discover How Key Protein Leads to Neurodegenerative Diseases
  
• University of Florida Receives $15M, and Berkeley Lab Obtains $12.8M in ARRA Funding
  
• Genentech and UCSF’s Small Molecule Discovery Center Ink Deal Targeting Neurodegenerative Diseases
  
• Genmab to Review Clinical Plans for Head and Neck Cancer Candidate after Mixed Results from Phase III Trial
  
• SeqWright and Lilly to Sequence Genomic Regions Associated with Psychiatric Diseases Using Roche Technologies
  
• PsychoGenics to Assess AstraZeneca Candidates for Treating Central Nervous System Disorders
  
• Biovail to Pay Cortex $10M for Ampakine Compounds against Respiratory Depression
  
• Evotec Wins €1.5M in German Federal Funding to Take H3 Receptor Blocker into Clinic
  
• AstraZeneca to Pay $520M Settlement in Seroquel Lawsuit
  
• TPP Raises £9.6M to Build Preclinical Pipeline
  
• Santhera Shares Drop 35% as Friedreich Ataxia Drug Fails in Phase III
  
• NeuroTherapeutics Scores $43M in Series B Financing Round